# US 2006/0153932 A1 · Method of treating hyperphosphataemia using lanthanum hydroxycarbonate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153932 A1
- Document ID: US20060153932A1
- Status: Published application
- Kind: A1
- Application number: 11/191,600
- Filed: 2005-07-27
- Published: 2006-07-13
- Earliest claimed: 2004-07-27
- Assignees: Shire Pharmaceuticals, Inc.
- Inventors: Josephine Ferdinando; David Gilmour
- Web page: https://patentgrep.com/patent/US20060153932A1

## CPC

- A61K 33/244: Lanthanides; Compounds thereof (medicinal preparations containing radioactive lanthanides for use in therapy or testing in vivo A61K51/00)
- A61P 13/12: of the kidneys
- A61P 3/12: for electrolyte homeostasis
- A61P 3/14: for calcium homeostasis (vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04)
- A61P 5/18: of the parathyroid hormones
- A61P 5/20: for decreasing, blocking or antagonising the activity of PTH
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to the treatment of subjects at risk for chronic kidney disease (CKD), having stage one to five CKD, having hyperphosphataemia, susceptible to or suffering from soft tissue calcification associated with CKD, or susceptible to or suffering from hyperparathyroidism, by orally administering a pharmaceutical composition containing a therapeutically effective amount of lanthanum hydroxycarbonate.

## Claims

### Claim 1

A method of treating a subject (1) at risk for chronic kidney disease (CKD), (2) having stage one to stage five CKD, or (3) susceptible to or suffering from soft tissue calcification associated with CKD, comprising orally administering to the subject a pharmaceutical composition containing as an active ingredient a therapeutically effective amount of lanthanum hydroxycarbonate.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is suffering from hyperphosphataemia.

### Claim 3 (depends on 1)

The method of claim 1, wherein the lanthanum hydroxycarbonate is administered to the subject in a daily dose ranging from 715 to 8586 mg.

### Claim 4 (depends on 1)

A method of claim 1, wherein the subject is suffering from renal failure, receiving dialysis or has end-stage renal disease.

### Claim 5

A method of treating hyperparathyroidism comprising administering to a patient in need thereof a therapeutically effective amount of lanthanum hydroxycarbonate.

### Claim 6 (depends on 5)

The method of claim 5, wherein the lanthanum hydroxycarbonate is administered to the subject in a daily dose ranging from 715 to 8586 mg.

### Claim 7 (depends on 5)

A method of claim 5, wherein said patient is suffering from renal failure, receiving dialysis or has end-stage renal disease.

### Claim 8

A pharmaceutical composition comprising lanthanum hydroxycarbonate and a pharmaceutically acceptable carrier.

### Claim 9 (depends on 8)

A pharmaceutical composition of claim 8, wherein the lanthanum hydroxycarbonate is present in from about 20 to about 60 percent by weight.
